

Time	Day 1	Day 2	Day 3	Day 4
	Sunday February 27	Monday February 28	Tuesday March 1	Wednesday March 2
8:30-9am		<u>Plenary</u> The Science and Practice of HIV Prevention in the US Jonathan Mermin <i>CDC, Atlanta, GA, US</i>	<u>Plenary</u> Cost-Effectiveness in HIV Care: Understanding Value in a World of Limited Resources Rochelle Walensky <i>Harvard Med Sch, Boston, MA, US</i>	<u>Plenary</u> Drugs for Prevention-Topical and Systemic PrEP Connie Celum <i>Univ of Washington Sch of Med and Sch of Publ Hlth and Community Med, Seattle, US</i>
9-9:30am	9 am-1:30 pm Program Committee Workshop for New Investigators and Trainees	<u>Plenary</u> Novel Neutralizing Antibodies Michel Nussenzweig <i>The Rockefeller Univ, New York, NY, US</i>	<u>Plenary</u> Structure of Integrase Peter Cherepanov <i>Imperial Coll London, UK</i>	<u>Plenary</u> HCV-Clinical/New Drugs Stefan Zeuzem <i>JW Goethe Univ Hosp, Frankfurt, Germany</i>
9:30-10am		Break	Break	Break
10am-12n		<u>Oral Abstracts</u> HIV-Host Interaction Prevention: HSV2, Topical and Oral PrEP, and Circumcision Opportunistic Infections and Complications Research on Delivery of Care in Developing Countries Innovative Therapeutic Approaches, Antiretroviral Therapy, and Drug Resistance	<u>Oral Abstracts</u> HIV Complications Virus-Cell Interaction and Cofactors Advances in Pre-exposure Prophylaxis	<u>Oral Abstracts</u> Mother-to-Child Transmission and HIV in Children HIV Transmission: Old Problems and New Insights HIV Immunopathogenesis and Protection Late Breaker Session
12n-1pm	Lunch	Lunch	Lunch	
1-2pm	1:45-2:30pm Lunch for Award/Scholarship Recipients	<u>Themed Discussions</u> Primate Viruses and How They Affect Humans Genomics and Pharmacogenetics: HIV Disease Progression, Antiretroviral Toxicity, and Response to HCV Therapy ART Use and Outcomes among Youth Cervical Cancer Screening in the Developing World: Lessons from Africa Retention and Adherence to Care in Resource Limited Settings	<u>Themed Discussions</u> Hematologic Malignancies Pharmacologic Considerations for Therapeutic Success/Failure in Resource Limited Settings Microbial Translocation and Immune Activation in HIV Infection and Therapy HAART during Pregnancy and Pre-term Delivery Cryptococcal Meningitis and Other Cryptic Diseases	<u>Themed Discussions</u> Biomarkers Linked to Cognitive Dysfunction Community Viral Load XMRV: New Findings and Controversies Is HIV Drug Resistance Spreading? Atherosclerosis and HIV Risk Factors and Pathogenesis
2-4pm		2:30-4:30pm Lab Science Workshop	<u>Poster Abstracts</u>	<u>Poster Abstracts</u>
4-6pm	2:30-4:30pm Trials Design Workshop	<u>Oral Abstracts</u> Viral and Host Factors in HIV Associated Neurological Disease	<u>Oral Abstracts</u> HCV Pathogenesis, Treatment, and Resistance	<u>Oral Abstracts</u> Factors Important in HIV Transmission
	4:30-5 pm Break	<u>Symposia</u> Anti-HIV Antibodies Responding to Risk HAART at 15	<u>Symposia</u> HPV Challenges and Opportunities Innate Immunity and Restriction Factors Getting the Most from Global HIV Scale-up	<u>Symposia</u> Obstacles to a Cure Colliding Epidemics: Controlling HIV-related Tuberculosis The HIV Epidemic at 30
6-7pm	5-7pm <u>Opening Plenaries</u> Bernard Fields Lecture Bryan Cullen <i>Duke Univ, Durham, NC, US</i>			
	N'Galy-Mann Lecture Anthony Harries <i>Intl Union against TB and Lung Disease, France</i>			
7-8:30pm	Welcome Reception			

Time	Monday, February 28	Tuesday, March 1	Wednesday, March 2
7 am-7 pm	Poster Halls open 7 am to 7 pm Monday through Wednesday All posters will be available for viewing for the duration of the conference		
2-4 pm	Poster Sessions		
	<p>HIV Entry and Cell-Cell Transmission</p> <p>Nuclear Import, Interaction, and Latency</p> <p>Viral Evolution and Host Adaptation</p> <p>Insights from Pathogenic versus Non-Pathogenic Infections</p> <p>Animal Models of HIV/SIV Pathogenesis</p> <p>Cellular Consequences of HIV Infection</p> <p>How HIV Affects Different CD4 T Cell Subsets</p> <p>What's New with PD-1</p> <p>What's New with NK Cells</p> <p>Innate Immunity</p> <p>CD4 T Cell Responses</p> <p>Pre-Clinical Testing of New Vaccine Concepts</p> <p>Cytokine Therapies for SIV/HIV Infection</p> <p>Predictors of HIV Associated Neuroclinical Disease Neuropathy</p> <p>Factors Affecting HIV Transmission</p> <p>Primary/Acute HIV Infection</p> <p>New Antiretroviral Agents, Targets, and Formulations</p> <p>Mechanisms of Resistance to Novel Entry Inhibitors</p> <p>Co-receptor Usage, Resistance to CCR5 Inhibitors, and Treatment Responses</p> <p>New Insights into NNRTI Resistance</p> <p>Pharmacokinetics and Drug Interactions of New and Existing Antiretroviral Agents</p> <p>HCV: Epidemiology and Diagnosis</p> <p>HCV: Natural History</p> <p>HCV: Immunology</p> <p>Causes of Death in Treated HIV</p> <p>Aging and HIV</p> <p>Inflammation and Coagulation</p> <p>Cardiovascular Disease: Outcomes and Predictors</p> <p>Atherosclerosis and HIV: Risk Factors and Pathogenesis</p> <p>HPV/Anal Cancer</p> <p>KSHV/Kaposi's Sarcoma</p> <p>Tuberculosis: Diagnosis and Case Finding</p> <p>Tuberculosis: Antiretroviral Therapy and Outcomes</p> <p>Cotrimoxazole for HIV and Malaria in Children</p> <p>HIV and ART Related Complications in Children and Youth</p> <p>Cardiovascular Complications and Dyslipidemias in Children and Youth</p> <p>Bone Complications and Treatment in Children and Youth</p> <p>HIV Drug Resistance and Tropism after Treatment Failure in Children</p> <p>Viral and Host Factors Associated with Pediatric HIV Infection</p> <p>Host Factors Associated with MTCT</p> <p>Risk Factors for MTCT</p> <p>Diagnostic Algorithms</p> <p>Topical and Oral PrEP: Preclinical and Animal Model Studies</p> <p>Clinical and Modelling Studies of Oral and Topical PrEP</p> <p>Male Circumcision: Scale-Up and Impact</p> <p>Sexually Transmitted Infections: HSV2 and Syphilis</p> <p>Epidemiology: Community Viral Load</p> <p>Epidemiology: Transmission</p> <p>Epidemiology: Risk Behavior</p> <p>Epidemiology: Networks of Infection</p>	<p>NEF, Tetherin and VPU</p> <p>XMRV: New Findings and Controversies</p> <p>XMRV and GBV Virus-Host Interaction</p> <p>Immune Reconstitution in the 21st Century</p> <p>Viral Dynamics on Raltegravir Intensification</p> <p>Studies of Chronic Infection</p> <p>New Insights from Superinfection</p> <p>Insights from Studies of Non-Progressive Infection</p> <p>Neutralizing versus ADCC Antibodies</p> <p>Neutralizing Antibodies to GP41</p> <p>Neutralizing Antibodies to GP120</p> <p>Choosing the Best Immunogen</p> <p>Antibodies as Therapy</p> <p>Targeting Immune Activation</p> <p>Biomarkers Linked to Cognitive Dysfunction</p> <p>Therapy of HIV Neurological Disease and CNS Penetration</p> <p>Imaging of HIV Neurological Disease</p> <p>Primate Viruses and How They Affect Humans</p> <p>Simian Viruses in South America</p> <p>Viral Genetics of Transmission</p> <p>Antiretroviral Therapy Strategies and Predictors of Response</p> <p>Novel Resistance Mechanisms, Assays, and Interpretations</p> <p>Resistance Profiles after First-Line Therapy</p> <p>Is HIV Drug Resistance Spreading?</p> <p>Clinical Pharmacology in Special Populations and Compartments</p> <p>HCV: Viral Pathogenesis and in vitro Studies</p> <p>HCV: Genetics</p> <p>HCV Treatment: Direct Acting Agents and Resistance</p> <p>HCV Treatment: Interferon and Ribavirin</p> <p>HCV: Treatment Impact</p> <p>Abacavir and Studies of Inflammatory Markers: Leukocyte Adhesion</p> <p>Antiretroviral Therapy and Lipid Changes: Randomized Clinical Trials</p> <p>Shedding Some More Light on Vitamin D and HIV</p> <p>Bone Disease: Fracture Risk and ART</p> <p>HIV, Tuberculosis, and Malaria</p> <p>Retention and Adherence to Care</p> <p>Retention and Outcomes in Resource-constrained Settings</p> <p>Cost and Impact of Pediatric Prevention and ART Programs in Resource-constrained Settings</p> <p>Risk Factors for HIV Acquisition among Youth</p> <p>ART Use and Outcomes among Youth</p> <p>HIV Disclosure in Children and Youth</p> <p>ART Pharmacokinetics during Pregnancy and Infancy</p> <p>Incidence and Prevention of PMTCT Associated Drug Resistance</p> <p>HPV Prevalence and Cervical Cancer Treatment</p> <p>Factors Associated with HIV Replication or Susceptibility in Women</p> <p>Cervical Cancer Screening in the Developing World: Lessons from Africa</p> <p>Nucleic Acid Detection</p> <p>Drug Resistance Testing</p> <p>Epidemiology: Testing</p> <p>Epidemiology: Identifying Recent Infection</p> <p>Epidemiology: Linkage to Care</p> <p>Epidemiology: Disease Progression</p>	<p>Uncoating, Reverse Transcription, and Assembly</p> <p>TRIM5, APOBEC, and Other Host Restriction Factors</p> <p>HIV Replication and Restriction in Macrophages</p> <p>The Latest on Cytokine Dysruption</p> <p>The Latest on Immune Activation</p> <p>Microbial Translocation and Immune Activation in HIV Infection and Therapy</p> <p>How the Gut Affects Pathogenesis</p> <p>CD8 T Cells and Virus Inhibition</p> <p>CD8 T Cell Cytolytic and Cytokine Function</p> <p>Phase I Human Trials of New Vaccine Strategies</p> <p>New Results From Therapeutic Vaccine Trials</p> <p>Neuro AIDS in Acute Infection</p> <p>HIV Neuropathogenesis: Immune Activations, Stress, Response and Viral Replication in the Brain</p> <p>Molecular Epidemiology, Transmission and Evolution HTLV-1</p> <p>Host Genomics</p> <p>Genomics and Pharmacogenetics: HIV Disease Progression, Antiretroviral Toxicity, and Response to HCV Therapy</p> <p>Mechanisms of Sexual HIV Transmission</p> <p>Antiretroviral Therapy Outcomes</p> <p>HIV-1 Subtypes, Viremia, and Immune Activation</p> <p>CD4 Cell Responses, Immune Activations, and Low-Level Viremia</p> <p>Antiretroviral Switching</p> <p>Novel Insights into PI Resistance</p> <p>Mechanisms of Raltegravir Resistance</p> <p>Pharmacologic Considerations for Therapeutic Success/Failure in Resource Limited Settings</p> <p>HCV: Microbial Translocation</p> <p>HBV: Natural History</p> <p>HBV: Vaccination</p> <p>HBV: Delta</p> <p>HBV: Treatment</p> <p>Renal Disease: Long Term Outcomes and Prognostic Factors</p> <p>Lipohypertrophy and Fat Loss</p> <p>Diabetes Mellitus and Glucose Metabolism</p> <p>Hyperlactatemia and Pancreatitis</p> <p>Immune Reconstitution Inflammatory Syndrome: Immunologic Predictors</p> <p>Hematologic Malignancies</p> <p>Cancer Epidemiology</p> <p>Cryptococcal Meningitis and Other Cryptic Diseases</p> <p>Opportunistic and Other Infections: Diverse Aspects H1N1 One Year Later</p> <p>HIV Testing and Linking to Care in Resource-limited Settings</p> <p>Antiretroviral Therapy Outcomes and Coverage in Resource-limited Settings</p> <p>Laboratory Monitoring of Antiretroviral Therapy in Resource-limited Settings</p> <p>Lopinavir/Ritonavir Pharmacokinetics, Safety, and Efficacy in Children</p> <p>ART Pharmacokinetics in Children</p> <p>Immune Response to Perinatal HIV and ART</p> <p>Response to Protective Vaccines in Children and Youth</p> <p>Antiretroviral Regimens and Prevention of Mother-to-Child Transmission</p> <p>HAART during Pregnancy and Pre-term Delivery</p> <p>PMTCT and Child Health Outcomes</p> <p>PMTCT and Maternal Health and Treatment Outcomes</p> <p>HIV Services, Diabetes, and Disease Progression in Women</p> <p>Tropism Assays</p> <p>CD4 Assays</p> <p>Recruitment and Retention of High Risk Populations: Enhancing Prevention and Linkage to Care</p>